Mepolizumab versus placebo for asthma

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 11, 2013, Pages

  Powell, Colin ^a   Milan, Stephen J ^b   Dwan, Kerry ^c   Walters, Nicola ^d  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEPOLIZUMAB; PLACEBO;

ARTICLE; ASTHMA; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; FORCED EXPIRATORY FLOW; HUMAN; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 85029872288     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010834     Document Type: Article

References (23)

1. Braman SS. The global burden of asthma. Chest 2006;130:4S-12S.
2. Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. A national clinical guideline. www.sign.ac.uk/pdf/sign101.pdf (accessed 10 December 2012).
3. Centers for Disease Control and Prevention. Vital signs. www.cdc.gov/vitalsigns/asthma/(accessed 10 December 2013).
4. Centers for Disease Control and Prevention. Trends in asthma prevalence, health care, and mortality in the United States, 2001-2010. www.cdc.gov/nchs/data/databriefs/db94.htm (accessed 10 December 2012).
5. Clayton S. Paediatric asthma: overcoming barriers to an improved quality of life. British Journal of Nursing 2005; Vol. 14, issue 2:80-5.
6. Gibson PG, Talbot PI, Hancock J, Hensley MJ. A prospective audit of asthma management following emergency asthma treatment at a teaching hospital. Medical Journal of Australia 1993;158:775-8.
7. Global Intitiative for Asthma. Pocket guide for asthma management and prevention (for adults and children older than 5 years). http://www.ginasthma.org/local/uploads/files/GINA_Pocket2013_May15.pdf (accessed 5 November 2013).
8. Haldar P, Brightling CE, Hargadon B, Gupta S, Monterio W, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England Journal of Medicine 2009;360:973-84.
9. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
10. Kandane-Rathnayake RK, Matheson MC, Simpson JA, Tang MLK, Johns DP, Mészáros D, et al. Adherence to asthma management guidelines by middle-aged adults with current asthma. Thorax 2009;64(12):1025-31.
11. Krishnan V, Diette GB, Rand CS, Bilderback AL, Merriman B, Hansel NN, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. American Journal of Respiratory and Critical Care Medicine 2006;174(6):633-8.
12. Liu Y, Zhang S, Li DW, Jiang S-J. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One 2013; Vol. 8, issue 3:e59872. [DOI: 10.1371/journal.pone.0059872]
13. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004;59:469-78.
14. Nair P, Pizzichini MMM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. New England Journal of Medicine 2009;360:985-93.
15. Health and Social Care Information Centre. Hospital Episode Statistics. www.hesonline.nhs.uk (accessed 10 December 2012).
16. National Institute for Health and Clinical Excellence. Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201). www.nice.org.uk/nicemedia/live/14157/63689/63689.pdf (accessed 5/11/13).
17. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma (EPR 3). www.nhlbi.nih.gov/guidelines/asthma/(accessed 10 December 2012).
18. Patel S, Jarvelin MR, Little M. Systematic review of worldwide variations of the prevalence of wheezing symptoms in children. Environmental Health 2009;7:57. [DOI: doi.10.1186/1476-069X-7-57]
19. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.
20. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
21. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases. A comprehensive approach. http://www.who.int/gard/publications/GARD%20Book%202007.pdf (accessed 5 November 2013).
22. World Health Organization. Health topics: asthma. www.who.int/topics/asthma/en/(accessed 13 September 2011).
23. Wu F, Takaro TK. Childhood asthma and environmental interventions. Environmental Health Perspectives 2007;115(6):971-5.